Brought to you by 
IPO nets $117.2mm for Versartis
24 Mar 2014
Executive Summary
Versartis Inc., which is developing treatments for growth hormone deficiency (GHD), netted $117.2mm in its initial public offering of 6mm common shares at $21.00. The company originally planned to sell 4.6mm shares between $16-19 each.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IPO nets $117.2mm for Versartis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice